Stock comparison
IDEXX Laboratories
Jazz Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
JAZZ
Jazz Pharmaceuticals
Market cap
$15.05B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | JAZZ | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 46D | IDXX |
| Benjamin Graham | 80A | 58D | IDXX |
| Philip Fisher | 75B | 42D | IDXX |
| Peter Lynch | 71B | 36D | IDXX |
| Joel Greenblatt | 83C | 44D | IDXX |
| Charlie Munger | 87A | 42D | IDXX |
| Terry Smith | 84A | 35D | IDXX |
Side-by-side metrics
| Metric | IDXX | JAZZ |
|---|---|---|
| Market cap | $44.12B | $15.05B |
| P/E (TTM) | 39.0x | 501.8x |
| EV/EBIT | 31.6x | 82.8x |
| ROIC (TTM) | 40.66% | -0.62% |
| Gross margin | 62.05% | 84.12% |
| Net margin | 24.63% | 0.66% |
| Revenue CAGR 5y | 7.56% | 8.37% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 1.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs -0.62%+102%
- Net margin24.63%vs 0.66%+97%
- P/E (TTM)39.0xvs 501.8x+92%
- Market cap$44.12Bvs $15.05B+66%
JAZZ leads on
- Gross margin84.12%vs 62.05%+26%
- Revenue CAGR 5y8.37%vs 7.56%+10%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.